DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Induction of Migraine Aura With Cilostazol

Information source: Herlev Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Migraine With Aura; Stroke

Intervention: Cilostazol (Drug); Placebo (Drug)

Phase: Phase 0

Status: Completed

Sponsored by: Herlev Hospital

Official(s) and/or principal investigator(s):
Christina Kruuse, MD PhD DMSc, Principal Investigator, Affiliation: Consultant Neurologist, Dept Neurology


In a double blind placebo-controlled cross-over study the effect of cilostazol on aura induction and endothelial response is tested in patient with migraine with aura.

Clinical Details

Official title: The Effect of the Selective PDE3 Inhibitor on Migraine With Aura Induction and Vascular Endothelial Function.

Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Primary outcome: Aura

Secondary outcome:


Endothelial response

Detailed description: Migraine with aura is associated to an increased risk of stroke. The mechanism behind such increased risk is not fully understood. Cilostazol induce headache and migraine in migraine patients and is used as secondary prevention of stroke. The effect on aura induction is not known. We investigate the aura inducing potential of cilostazol and associated changes in endothelial function.


Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.


Inclusion Criteria:

- Migraine with aura

- Minimum of 2 attacks/year

Exclusion Criteria:

- Chronic tension type headache

- Cardiac arrhythmias

Locations and Contacts

Herlev Hospital, Dept Neurology, Herlev 2730, Denmark
Additional Information

Starting date: September 2014
Last updated: August 20, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017